The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer.

@article{Monzon2009TheRO,
  title={The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer.},
  author={Federico A. Monzon and Shuji Ogino and M Elizabeth Hale Hammond and Kevin C. Halling and Kenneth J. Bloom and Marina N. Nikiforova},
  journal={Archives of pathology & laboratory medicine},
  year={2009},
  volume={133 10},
  pages={
          1600-6
        }
}
CONTEXT KRAS mutations can be detected in approximately 30% to 40% of all patients with colorectal cancer. Several recent studies have shown that patients with KRAS mutations in codons 12 or 13 in metastatic tumors do not benefit from anti-epidermal growth factor receptor therapy with cetuximab or panitumumab. OBJECTIVE To review the literature on the role of KRAS mutation testing for management of patients with metastatic colorectal cancer and to discuss testing strategies. DATA SOURCES… CONTINUE READING
BETA

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 54 CITATIONS, ESTIMATED Infinity% COVERAGE

54 Citations

051015'10'12'14'16'18
Citations per Year
Semantic Scholar estimates that this publication has 54 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
SHOWING 1-10 OF 42 REFERENCES

Similar Papers

Loading similar papers…